Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aanjaay Industries has informed that a meeting of the Board of Directors of the Company is scheduled to be held on 02nd September 2026 at the Corporate Office of the Company situated at Chennai, to consider and approve the following business: 1. To approve Director’s Report and Corporate Governance Report for the financial year ended 31st March 2026. 2. To approve closure of Register of Members and Share Transfer Books of the Company for Annual General Meeting (AGM) purpose. 3. To approve the Cut-off date to record the entitlement of shareholders to cast their votes for the Annual General Meeting (AGM). 4. To fix the Date, Time and Venue to convene the Annual General meeting of the Company & the draft Notice calling the Annual General Meeting (AGM). 5. To consider and approve appointment of scrutinizer for Annual General Meeting (AGM) purpose. 6. To consider and recommend the re-appointment of Kuniamuthur Nanjappan Anand (DIN: 03230186), Director of the Company, who retires by rotation at the ensuing Annual General Meeting 7. To consider and approve the appointment of Internal Auditors of the Company for the financial year 2026-2027. 8. To recommend the appointment of Moonam Kapoor (DIN: 09278005) as Director of the Company. 9. To recommend the appointment of Secretarial Auditor of the Company for the financial year 2026-2027 to 2030-2031. 10. Any other agenda with permission of chair.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1900.50 |
| Dr. Reddys Labs. | 1175.00 |
| Cipla | 1419.90 |
| Lupin | 2164.60 |
| Zydus Lifesciences | 1189.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: